Science & Standards
Four sectors One evidence discipline
The programme now spans industrial quality control, large-organ source science, consumer delivery practices and precision diagnostics.
01APAC Guidance for Industrial Manufacturing and Quality Control of Targeted Extracellular Vesicles (TEVs)A measurable reference framework for reproducible manufacturing, particle grading and non-invasive consumer-use safety.
As targeted extracellular vesicles (TEVs) move from laboratory research towards scalable applications, reproducible manufacturing, particle uniformity, stability and safety have become shared priorities across Asia Pacific. This guidance offers research institutions, ingredient manufacturers and application partners a measurable reference for consumer-grade TEV production and quality control.
Asia-Pacific industry progress
- The region is progressing from small-scale extracellular-vesicle research towards industrial production, while batch consistency, transdermal-performance evaluation and room-temperature stability remain common challenges.
- tiptop, the technology platform of Tiptop Human Longevity Biotechnology Research Institute Limited, provides one regional practice example: consumer-grade screening, purification, lyophilisation, stability assessment and batch management are coordinated with Japan-based production and quality management through 株式会社丸誉長寿バイオテック研究院.
- The TASCAP Expert Committee encourages transparent methods, comparable measurements and clear evidence boundaries so that advanced practices can be evaluated and improved across the industry.
Nine proposed quality-control indicators
- TEM: intact, non-aggregated bilayer vesicle morphology.
- NTA: 30–150 nm main distribution; proposed main-peak share ≥85%, with 50–120 nm treated as a working delivery interval.
- Particle concentration: proposed intermediate threshold ≥1.0 × 10¹¹ particles/mL.
- Positive markers: CD63, CD9 and CD81 by WB/ELISA.
- Negative marker: Calnexin absent to reduce cellular-debris contamination.
- Batch protein variation within ±15% as a proposed manufacturing-control target.
- Bacteria, fungi and mycoplasma negative.
- LAL endotoxin target <0.5 EU/mL.
- Lead, arsenic, mercury and cadmium controlled against applicable cosmetic limits and validated methods.
Proposed particle grades
- Grade I: 50–120 nm, main peak ≥90%.
- Grade II: 50–120 nm, main peak ≥95%; batch CV <10%.
- Grade III: 70–90 nm, main peak ≥99%.
Four-layer evidence and safety chain
- Raw material: batch COA and complete SDS.
- Non-animal / in-vitro: cytotoxicity, OECD 432 phototoxicity and OECD 439 reconstructed epidermis irritation where applicable.
- Human-use tolerance: HRIPT and 28-day observational use under an approved protocol.
- Delivery evidence: claims linked to appropriately designed penetration or molecular-pathway studies.
Compliance boundary
- Cell-free material only; no live-cell implication.
- Not for invasive injection.
- No diagnosis, treatment or cure claims; consumer communication must follow local law.
02Large-Organ-Source Regenerative Science, Frontier Mechanisms and International Compliance PracticeA source-to-evidence view of homologous adaptation, ethics, public research and ingredient-name registrations.
The specificity and safety of advanced extracellular-vesicle technologies begin with tissue and cell source. This sector examines homologous adaptation, source ethics, organ-derived regenerative science and international ingredient registrations through a representative Asia-Pacific pathway linking The ZUO Lab., Regend and tiptop.
From source science to consumer-grade translation
- Professor Wei Zuo (Zuo W.) and Dr. Ting Zhang (Zhang T.) are key scientific figures associated with The ZUO Lab. and Regend’s translation pathway in stem-cell, extracellular-vesicle and tissue-regeneration research.
- Regend is one of tiptop’s extracellular-vesicle-related raw-material suppliers. Wei Zuo and Ting Zhang participate in technical exchange with tiptop as scientific translation advisers, including manufacturing, purification, lyophilisation stability, particle-size control, quality evaluation and batch consistency.
- tiptop operates under 北中創科長壽健康生命科技有限公司 / Tiptop Human Longevity Biotechnology Research Institute Limited. Following documented procurement, its role focuses on consumer-grade screening, purification, stability and production translation, with Japan-based manufacturing and quality management coordinated through 株式会社丸誉長寿バイオテック研究院.
- CELLshot and 不老の藍图 are powered by tiptop consumer brands. The research publications below provide source-level scientific context rather than direct efficacy evidence for any finished cosmetic product.
Homologous adaptation
- MenSC-EVs: research interest in epithelial and barrier biology associated with P63+/SOX9+ signalling.
- Kidney tubule epithelial stem-cell derivatives: organ-source signalling studied in relation to SOX9+ progenitor biology.
- Organ-source relevance, targeting and delivery performance require direct validation for the intended material, formulation and use.
Source ethics and risk matrix
- Human organ-source cells: informed consent, independent ethics/IRB review, de-identification and appropriate GMP controls.
- Microbial source: non-pathogenic strain identity, genome-level characterization and applicable GRAS/QPS context.
- Plant / fermentation source: sustainable sourcing and clear disclosure that broad delivery is not organ-specific targeting.
International ingredient-name registrations
- Human Endometrial Stem Cell Exosomes — INCI Mono ID 39006; JCIA reference 22788.
- Human Kidney Tubule Epithelial Stem Cell Extract — INCI Mono ID 37568; JCIA reference 22787.
- Registration status, scope and permitted claims should be confirmed in the relevant jurisdiction before use.
Public evidence chain
- Zuo W. et al.: p63+Krt5+ distal airway stem cells and lung regeneration (Nature; PMID 25383540; DOI 10.1038/nature13903).
- Autologous P63+ lung progenitor-cell transplantation in COPD (Science Translational Medicine; PMID 38354225; DOI 10.1126/scitranslmed.adi3360).
- Zhang T., Zuo W. et al.: cloned airway basal progenitor cells and re-epithelialisation (Nature Communications; PMID 39900892; DOI 10.1038/s41467-025-56501-w).
- The FDA record confirms orphan designation for a Regend-sponsored autologous airway-basal-cell product for IPF; it also states that the product is not FDA-approved for the orphan indication.
- ClinicalTrials.gov registrations are research records, not evidence for consumer cosmetic efficacy.
03ATDS Advanced Practices for Consumer Transdermal and Mucosal Delivery in Asia PacificA proposed measurement language for topical skincare, scalp care and non-invasive mucosal delivery.
The global personal-care market is moving from an emphasis on ingredient concentration towards a closer examination of delivery and absorption. This sector shares ATDS—Advanced Transdermal Delivery Standards for Consumer Anti-aging—a whitepaper and industrial quality-acceptance framework published by tiptop for topical skincare, scalp care and non-invasive mucosal applications.
tiptop ATDS advanced-practice case
- ATDS is published by tiptop, the consumer-grade technology platform of Tiptop Human Longevity Biotechnology Research Institute Limited.
- Its Japan-based subsidiary, 株式会社丸誉長寿バイオテック研究院, coordinates production, formulation stability and quality-management practices.
- The framework brings industrial manufacturing, carrier uniformity, transdermal-performance evaluation and non-medical safety validation into one measurable reference system.
- ATDS is an industry whitepaper and practice framework—not a government regulation, medical-use standard or substitute for jurisdiction-specific review.
Barrier-specific application map
- Facial skincare: stratum-corneum and follicular-route evaluation for 30–150 nm carriers.
- Scalp care: follicular-infundibulum delivery and retention near the follicular unit.
- Non-invasive oral-mucosal products: carrier balance, formulation safety and local food/supplement regulation.
Industrial acceptance indicators
- Carrier morphology and integrity.
- 30–150 nm distribution with proposed main peak ≥85%.
- Proposed particle concentration ≥1.0 × 10¹¹ particles/mL.
- Positive carrier markers and negative impurity markers.
- Batch composition variation within ±15%.
- Microbial, endotoxin and elemental-impurity controls appropriate to intended use.
Proposed ATDS absorption grades
- Grade 0: main peak ≥85%.
- Grade I: ≥90%, with large aggregates excluded.
- Grade II: ≥95%, with formulation-stability evidence.
- Grade III: 70–90 nm enriched, main peak ≥99%; any superior-absorption claim still requires direct comparative testing.
Three-part non-medical validation chain
- Franz diffusion-cell testing for cumulative permeation.
- Reconstructed human epidermis or another fit-for-purpose barrier model.
- Third-party patch testing / HRIPT for routine-use tolerance.
Boundary
- External, non-invasive consumer use only.
- Not a drug, diagnostic method or substitute for treatment.
- Absorption improvement does not by itself prove clinical benefit.
04Precision Diagnostics, Aging Clocks and Screening StandardsInterpretation standards for epigenetic age, telomeres, methylation-based cancer screening and multi-omics.
Testing can support risk discussion and longitudinal observation, but analytical validity, clinical validity and clinical utility must be assessed separately. No single biological-age score should be treated as a diagnosis.
Epigenetic aging clocks
- Disclose clock version, tissue type, reference population and uncertainty.
- Avoid treating change in a score as proof of rejuvenation without validated outcome linkage.
- Use the same laboratory and method for longitudinal comparisons where possible.
Telomere testing
- Report method, specimen, age-adjusted reference and assay variation.
- Population association is not an individual prognosis.
- Repeat testing requires a pre-defined interval and interpretation plan.
Methylation-based cancer screening
- Use only tests with clearly stated intended use, sensitivity, specificity and confirmatory pathway.
- A positive screening signal is not a cancer diagnosis; a negative result does not eliminate risk.
- Clinical referral and jurisdiction-specific approval are mandatory.
Multi-omics and biomarkers
- Predefine the decision the panel is intended to support.
- Control false discovery, multiple comparisons and incidental findings.
- Protect genomic privacy and obtain appropriate consent.